9 withdrawn. 9 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Withdrawn 9 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL Pelacarsen, Placebo - Acute Coronary Syndrome (ACS) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2026-09-01 | 2026-10-14 | |
| Earlier Mobilization Post Acute Thrombolysis Mobilization - Stroke, Stroke, Acute | Phase 3 | Withdrawn | Brian Silver | 2023-08-01 | 2023-10-30 | |
| Earlier Mobilization Post Acute Thrombectomy Mobilization - Stroke, Stroke, Acute | Phase 3 | Withdrawn | Brian Silver | 2023-08-01 | 2023-10-30 | |
| Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease Liraglutide Pen Injector [Victoza], Placebo - Type 2 Diabetes, Cardiovascular Diseases | Phase 3 | Withdrawn | RWTH Aachen University | 2020-11-01 | 2021-03-10 | |
| Coronavirus Response - Active Support for Hospitalised Covid-19 Patients Aspirin, Losartan, Simvastatin - Covid-19 | Phase 3 | Withdrawn | London School of Hygiene and Tropical Medicine | 2020-10-01 | 2020-11-19 | |
| Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention. Ticagrelor, Clopidogrel - Diabetes Mellitus, Microvascular Coronary Artery Disease | Phase 3 | Withdrawn | Region Skane | 2019-09-15 | 2020-04-08 | |
| DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization DLBS1033, Placebo - Acute Non-ST Elevation Myocardial Infarction | Phase 2 / Phase 3 | Withdrawn | Dexa Medica Group | 2015-11-01 | 2016-04-20 | |
| Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) Tenecteplase, Alteplase - Ischemic Stroke | Phase 2 / Phase 3 | Withdrawn | Reza Behrouz, DO | 2015-01-01 | 2015-09-23 | |
| Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention Tirofiban (Aggrastat), Placebo - Myocardial Infarction, Acute Coronary Syndromes | Phase 3 | Withdrawn | Medicure | 2018-03-13 |
Myocardial Infarction (4) · Ischemic Stroke (3) · Acute Coronary Syndrome (2) · Brain Diseases (2) · Cerebrovascular Disorders (2) · Non-ST Elevated Myocardial Infarction (2) · Stroke (2) · Angina, Unstable (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Cerebral Infarction (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Pneumonia (1)
Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Vascular Diseases (9) · Cardiovascular Diseases (8) · Infarction (7) · Necrosis (7) · Heart Diseases (6) · Myocardial Ischemia (6) · Central Nervous System Diseases (3) · Nervous System Diseases (3) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Myocardial Infarction (2)
Aspirin (1) · Clopidogrel (1) · DLBS 1033 (1) · Liraglutide (1) · Losartan (1) · Simvastatin (1) · Tenecteplase (1) · Ticagrelor (1) · Tirofiban (1) · Tissue Plasminogen Activator (1) · pelacarsen (1)
Brian Silver (2) · Dexa Medica Group (1) · London School of Hygiene and Tropical Medicine (1) · Medicure (1) · Novartis Pharmaceuticals (1) · RWTH Aachen University (1) · Region Skane (1) · Reza Behrouz, DO (1)
Germany (1) · Indonesia (1) · Nigeria (1) · Pakistan (1) · United States (1)
Brian Silver, MD (2) · Haleema Shakur-Still (1) · Ian Roberts (1) · Ismi Purnawan, SpJP(K), MD (1) · Muhammad Munawar, SpJP(K), MD (1) · Reza Behrouz, DO (1) · Steven V Manoukian, MD (1)
2019 (1)